-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
NCCN Guidelines Update and Interpretation Expert Introduction
First- and second-line treatment of CLL/SLL preferred status
In recent years, the treatment of CLL/SLL has undergone a historic changeThe 2022 NCCN CLL/SLL Guideline V2[2] has included zebutinib in the preferred recommended treatment status for the CLL/SLL first- and second-line lines
Zebutinib brings longer survival to CLL/SLL
In fact, for the treatment of CLL/SLL patients, the first-generation BTK inhibitor ibratinib ushered in the era of
A large global phase III ALPINE study comparing the generation of BTK inhibitor ibretinib in the global study[4], zebutinib vs.
The 2023 LCCN CLL/SLL guideline V1 transfers the generation of BTK inhibitor ibratinib from the original priority recommendation to other recommended protocols in all first- and second-tier populations
In the ALPINE head-to-head comparison study with ibretinib, the incidence of atrial flutter/atrial fibrillation in the zebutinib group was 2.
Click "Read the original article" to see more information
